Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eliglustat + ICI +/- Regorafenib in pMMR/MSS Colorectal Cancer
NCT06558773Phase 2Recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Mar 2026
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of eliglustat in colorectal cancer (CRC), sponsored by Chinese PLA General Hospital. Started Mar 2026; status: recruiting.
02
Drugs
eliglustat
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06558773.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06558773.